The effects of hepatitis B virus (HBV) on established human cell lines of various tissue origins were evaluated by clonal or colorimetric assays in methylcellulose culture. HBV exposure inhibited the growth of six hemopoietic cell lines, while similar incubation did not affect the growth of seven nonhemopoietic carcinoma cell lines of breast, colon, liver, and stomach origin. The inhibition of hemopoietic cell line colony formation was dependent on the presence of intact viral (Dane) particles and the ratio of exposure of virions to cells and was reversible with antibodies to pre-Sl, pre-S2, and S envelope protein epitopes. Purified HBV DNA, surface antigen pre-S antigens, and core antigen did not inhibit cell line growth. These results further demonstrate the tropism of HBV for cells of hemopoietic origin, confirming our previous findings on the effects of HBV on the growth of normal bone marrow progenitor cells in vitro. Established human tissue culture cell lines may be used to study the interactions of hemopoietic cells with HBV.
Hepatitis B virus (HBV) is not exclusively hepatotropic. HBV DNA has been detected in pancreas, kidney, skin (4), bone marrow (5, 9) , and peripheral blood mononuclear cells (7, 8) . Romet-Lemonne et al. (9) and Elfassi et al. (5) have shown that viral antigens and HBV DNA are present in a small percentage of bone marrow cells from infected patients. We have found that the in vitro growth of human bone marrow progenitor cells is suppressed after exposure to HBV (15) . This inhibition is dependent on the ratio of the number of virions per mononuclear cell and can be blocked by antibody to HBV surface antigen (HBsAg) (14) . Since cell lines of hemopoietic origin are more readily available than normal bone marrow cells, it was of interest to examine the effects of HBV on the growth of cell lines as a potential model for HBV infection.
MATERIALS AND METHODS
Virus. Virus-containing sera were obtained from patients with chronic HBV infections. The sera lacked serologic evidence of human immunodeficiency virus infection. Sera were filtered through 0.22-mm-pore-size filters and stored at -20°C. Virion (Dane particle) preparations (14) and plasma and recombinant-derived small HBsAgs were gifts of William Miller, Merck, Sharp, Dohme (West Point, Pa.). HBV was also produced by growing, in RPMI 1640 with 10% fetal bovine serum (FBS), a hepatoblastoma cell line, HepG24, that was transformed with HBV DNA, obtained from G. Acs formed in the experimental group was compared with the number formed after incubation with control sera. The data are expressed as percent inhibition.
Cell growth was alternatively studied by a modified assay (2) . This assay measures labile cellular dehydrogenases that are only found in viable cells. Briefly, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan bromide (MTT; Sigma) was added to each culture and incubated for 4 h at 37°C and 5% CO2. The cultures were harvested, and the formazan particles were pelleted and solubilized in 100% dimethyl sulfoxide (Sigma). A portion of the solution was transferred to a 96-well plate, and the OD490 was measured.
Antibody neutralization studies. Before the cells were exposed to virus, HBV preparations (sera or purified virions) were incubated for 4 h at 37°C with polyclonal antisera, supernatants from hybridoma cultures, or diluted murine ascites containing monoclonal antibodies. The percent neutralization was calculated by the following formula: 
RESULTS
The results of the colony-forming assay and the MTT assay correlated well with each other. Serum devoid of HBV did not affect the growth of any cell line as measured by either assay. Incubation of hemopoietic cell lines K562 and U937 with serial dilutions of HBV DNA sera resulted in a dose-dependent inhibition of their clonal growth in methylcellulose as measured by either assay (Fig. 1) . The number of cells in the colonies that formed in the presence of HBV was no different than that found in cultures of cells not exposed to virus. After HBV exposure, many cells were found in suspension, not associated with colonies. Most of these cells were viable after 5 days in culture in that they excluded trypan blue stain. HBV-containing sera inhibited the growth of all six human hemopoietic cell lines in a dose-dependent manner (Fig. 2) , while the same sera did not inhibit the growth of three nonhemopoietic cell lines of breast, colon, and stomach origin (Fig. 3) . The growth of liver-derived cell lines PLC/PRF/5, HepG2, HepG2T14, and HepG24 was also unaffected by HBV (data not shown). The last two lines were actively making HBV. Hemopoietic cell lines derived from T cells (CEM and Jurkat) appeared to be more sensitive to HBV than lines of myeloid (HL60, U937) or B-cell (JY) origin. At a 1:1,000 dilution of sera, inhibition of the T-cell lines occurred, whereas little or no suppression was observed in U937, HL60, and JY cells (Fig. 2) .
The degree of K562 and HL60 inhibition was proportional to the ROE of virus to cells, as determined by the number of HBV DNA molecules incubated per cell (Fig. 4) Fig. 1 and 2 . The OD490 of the controls was 0.220 ± 0.020 for T47D, 0.233 ± 0.010 for B5637, and 0.540 ± 0.010 for C247.
K562 was still observed at 3 virions per cell. Experiments with purified virions were performed to eliminate the possibility that factors in HBV-containing sera other than virus were responsible for the suppressive effect on hematopoietic cell line growth. An ROE of 3 x 104 virions per cell inhibited K562 and HL60 cells by 45 and 30%, respectively (Fig. 5A) . In all experiments, more than 1 virus per cell was required to observe cell growth inhibition. Virus purified from the supernatants of HepG24 cells also inhibited colony formation. While both HBV-containing sera and purified virions inhibited hematologic cell line growth, heat-inactivated virions, purified plasma-derived small HBsAg and yeast-derived recombinant small HBsAg, recombinant HBcAg, pre-SI and pre-S2 synthetic polypeptides, and purified viral DNA derived from sera did not suppress K562 or HL60 colony formation even at concentrations consistent with a very high ROE (Fig. SC) .
Antibodies to surface epitopes on virions neutralized the HBV-mediated inhibition of cell line growth (Fig. 5) . At an ROE of 3 x 104 virions per cell, 1:10 and 1:100 dilutions of murine ascites containing 5D3, an anti-HBsAg monoclonal antibody, neutralized the inhibitory effects of HBV on K562 and HL60 growth (Fig. SB) . The (Fig. 5D) (Fig. 5D) , which has been demonstrated to be infectious for chimpanzees (1) . As with the human progenitor cell assays, a lower ROE with HBV-containing sera was required to inhibit cell growth than with purified virus in the Dane particle preparations (14) . This difference may reflect inactivation of 10 -fold in RPMI 1640 and incubated for 2 h at 37°C with purified HBsAg and pre-S antigens; Meas, culture supernatant for a murine hybidoma with antibody specificity for the measles virus; IgG, murine ascites from a monoclonal hybridoma with anti-human immunoglobulin specificity; D-preS, culture supernatant for a murine hybidoma with antibody specificity for the pre-S region of duck hepatitis virus (this antibody does not bind the pre-S and S regions of HBV); and WHs, murine ascites from a monoclonal hybridoma with anti-woodchuck hepatitis virus surface antigen specificity (this monoclonal antibody binds to the S region of HBV).
virions resulting from the various purification steps used to make the Dane particle preparation. The suppression of cell growth by purified virions and tissue culture-derived virus supports the hypothesis that the mechanism of inhibition involves a direct effect of the virus and not some other component found in serum. This hypothesis is also supported by our observations that antibodies to pre-SI, pre-S2, and S envelope proteins neutralized HBV inhibitory effects on colony formation. Since only viral particles contain pre-Sl sequences and since anti-pre-Sl antibodies neutralized the growth inhibition, these results imply that intact virus is involved in the inhibition of colony formation. This conclusion is also strengthened by the observation that incubation of anti-HBsAg monoclonal antibodies with HBsAg and pre-S antigens abolished the antibodies' ability to neutralize HBV-mediated inhibition of K562 colony formation. In addition, antibodies to epitopes unrelated to the envelope proteins of HBV (antibodies to duck hepatitis virus, measles virus, and human immunoglobulins) had no effect on HBV inhibition of colony formation. Only antibodies that cross-reacted with HBsAg neutralized the HBV effect.
Although we have previously found a direct effect of HBV on the growth and differentiation of bone marrow progenitor cells, we could not exclude that minor contamination of these cells with accessory cells somehow released substances that resulted in inhibition. The This failure might reflect the inhibitory effects of HBV on cell growth, as were observed in the hemopoietic cell lines.
In conclusion, hemopoietic cell lines may be used to study the relationships between HBV and abnormalities of hemopoiesis associated with viral hepatitis. This model may complement other recently described in vitro HBV culture models, including HBV-infected human B cell hybridomas (3), transfected hepatoma and hepatoblastoma cell lines (10, 11) , and HBV-infected human hepatocytes (6) . 
